BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is one of the 10 oversold small cap stocks to buy now.

On April 21, BofA analyst Alec Stranahan reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to $41 from $44, while maintaining a Buy rating on the stock. Stranahan highlighted that Agios intends to seek accelerated approval and has already filed a proposal for a confirmatory trial with an updated primary endpoint.

Tonhom1009/Shutterstock.com

Nevertheless, the analyst noted that topline results of the HIBISCUS study of Novo Nordisk’s etavopivat for sickle cell disease will pose a regulatory risk for Agios’ mitapivat. Despite such competitive risks, the stock is still amongst the best oversold small-cap names right now.

On April 20, H.C. Wainwright analyst Emily Bodnar reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) from $65 to $50, while maintaining a Buy rating on the stock. She attributed this downward revision to Novo Nordisk’s HIBISCUS Phase 3 trial, noting that both primary endpoints were met, which is sure to result in success for sickle cell disease.

Novo’s etavopivat is taken once a day compared to Agios’ mitapivat taken twice a day. Given that Novo offers multiple medications for preventing hemorrhages in hemophilia A/B patients, the company expects to secure a large market share, according to the analyst. The HIBISCUS data is expected to reduce the commercialization potential of mitapivat.

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is engaged in discovering and creating therapeutics in the field of cellular metabolism in the United States. It offers a range of drugs for different illnesses. Its product offering includes PYRUKYND (mitapivat), AQVESME, tebapivat, AG-181, and AG-236.

While we acknowledge the risk and potential of AGIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AGIO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.